ReviewSeminars in immunopathology2019
Cancer immune therapy for lymphoid malignancies: recent advances.
Review in Seminars in immunopathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- IL-18-armed oncolytic vaccinia virus remodels the suppressive microenvironment via macrophage and Treg modulation in lymphoma.Cancer immunology, immunotherapy : CII · 2026Article
- Comprehensive analysis of immune-related genes reveals diagnostic biomarkers and molecular subtypes in diabetic retinopathy.PloS one · 2026Article
- Causal association between endocrine diseases and lymphoid malignancies explored through two-sample Mendelian randomization analysis.Scientific reports · 2025Article
- CAR-T Therapy in Relapsed Refractory Multiple Myeloma.Current medicinal chemistry · 2024Review
- Immune Infiltration in Gastric Cancer Microenvironment and Its Clinical Significance.Frontiers in cell and developmental biology · 2021Article
- An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma.Oncoimmunology · 2021Article
- Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress.Annals of hematology · 2020Review
- A novel targeted GPC3/CD3 bispecific antibody for the treatment hepatocellular carcinoma.Cancer biology & therapy · 2020Article
- How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Review
- Humanized mouse models of immunological diseases and precision medicine.Mammalian genome : official journal of the International Mammalian Genome Society · 2019Review
- T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances.Journal of cancer research and clinical oncology · 2019Review
- Anti-cancer immunotherapy: breakthroughs and future strategies.Seminars in immunopathology · 2019Article
- Genetically engineered T cells for cancer immunotherapy.Signal transduction and targeted therapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy has played an important part in improving the life of patients with lymphoproliferative diseases especially since the addition of rituximab to chemotherapy in the CD20-positive neoplasms in the 1990s. While this field of passive immunotherapy is continuously evolving, several breakthroughs will expand the treatment modalities to include more active immunotherapy. With the approval of immune checkpoint-blocking antibodies for Hodgkin lymphoma and bispecific antibodies for acute lymphoblastic leukemia (ALL), activation of endogenous T cells already plays a role in several lymphoid malignancies. With the approval of cellular therapies with CAR-T cells for ALL and diffuse large B cell lymphoma, the impact of the manipulation of immune responses is taken even further. Vaccines are cellular therapies in the opposite end of the spectrum in terms of side effects, and while the big breakthrough is still to come, the prospect of a very low-toxic immunotherapy which could be applicable also in premalignant states or in frail patients drives a considerable research activity in the area. In this review, we summarize the mechanisms of action and clinical data on trials in the lymphoid neoplasms with chimeric antigen receptor T cells, bispecific antibodies, immune checkpoint-blocking antibodies, and antineoplastic vaccination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.